

# David A Isenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2161950/publications.pdf>

Version: 2024-02-01

570  
papers

42,688  
citations

3159

92  
h-index

2895

190  
g-index

597  
all docs

597  
docs citations

597  
times ranked

25915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 363-369.	6.7	2,042
3	Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2008, 358, 929-939.	27.0	1,548
4	Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community. <i>Arthritis and Rheumatism</i> , 1993, 36, 340-347.	6.7	1,477
5	CD19 <sup>+</sup> CD24 <sup>hi</sup> CD38 <sup>hi</sup> B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients. <i>Immunity</i> , 2010, 32, 129-140.	14.3	1,382
6	Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNF $\alpha$ Therapy. <i>Journal of Experimental Medicine</i> , 2004, 200, 277-285.	8.5	1,112
7	Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 222-233.	6.7	1,111
8	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1103-1112.	6.1	923
9	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
10	Systemic lupus erythematosus. <i>Lancet, The</i> , 2014, 384, 1878-1888.	13.7	639
11	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
12	CD19 <sup>+</sup> CD24 <sup>hi</sup> CD38 <sup>hi</sup> B Cells Maintain Regulatory T Cells While Limiting T <sub>H</sub> 1 and T <sub>H</sub> 17 Differentiation. <i>Science Translational Medicine</i> , 2013, 5, 173ra23.	12.4	564
13	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
14	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2011, 365, 1886-1895.	27.0	544
15	An open study of B lymphocyte depletion in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 46, 2673-2677.	6.7	539
16	BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 902-906.	1.9	490
17	Malignant lymphoma in primary Sjögren's syndrome: A multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1999, 42, 1765-1772.	6.7	468
18	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391

#	ARTICLE	IF	CITATIONS
19	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
20	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e426-e436.	4.6	322
21	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , 2004, 43, 49-54.	1.9	311
22	A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. <i>Immunity</i> , 2016, 44, 683-697.	14.3	303
23	Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology</i> , 2010, 49, 128-140.	1.9	290
24	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. <i>Arthritis Care and Research</i> , 2011, 63, S118-57.	3.4	288
25	Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL- <i>lpr</i> Mice. <i>Journal of Immunology</i> , 2009, 182, 3492-3502.	0.8	269
26	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
27	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 972-979.	6.7	252
28	Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2003, 13, 137-147.	2.9	250
29	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
30	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
31	Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. <i>Rheumatology</i> , 2007, 46, 1052-1056.	1.9	244
32	A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 482-487.	6.7	241
33	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
34	Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. <i>Arthritis and Rheumatism</i> , 2000, 43, 1431-1442.	6.7	229
35	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
36	The mosaic of autoimmunity. <i>Trends in Immunology</i> , 1989, 10, 123-126.	7.5	218

#	ARTICLE	IF	CITATIONS
37	Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. British Journal of Haematology, 2001, 115, 451-459.	2.5	217
38	A comparative analysis of disease-associated changes in the galactosylation of serum IgG. Journal of Autoimmunity, 1989, 2, 101-114.	6.5	213
39	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmunity Reviews, 2012, 11, 357-364.	5.8	209
40	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology, 2009, 48, 673-675.	1.9	204
41	Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney International, 1995, 48, 705-711.	5.2	196
42	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 266-276.	5.6	184
43	Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T Cells. Immunity, 2012, 36, 477-490.	14.3	174
44	Measures of adult systemic lupus erythematosus: Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAMRA), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care and Research, 2011, 63, S37-46.	3.4	173
45	Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clinical Immunology and Immunopathology, 1984, 31, 261-271.	2.0	168
46	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. Journal of Clinical Investigation, 2004, 113, 1176-1187.	8.2	156
47	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
48	Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. British Journal of Rheumatology, 2003, 42, 1168-1172.	2.3	146
49	B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Annals of the Rheumatic Diseases, 2007, 66, 1259-1262.	0.9	145
50	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
51	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis and Rheumatism, 2010, 62, 211-221.	6.7	139
52	Mycobacteria and autoimmunity. Trends in Immunology, 1988, 9, 178-182.	7.5	135
53	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human $\beta$ 2-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis and Rheumatism, 2007, 56, 280-290.	6.7	134
54	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.9	132

#	ARTICLE	IF	CITATIONS
55	Antiribosomal p Protein Antibodies in Systemic Lupus Erythematosus. Arthritis and Rheumatism, 1994, 37, 307-315.	6.7	130
56	Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. Journal of Clinical Investigation, 2014, 124, 712-724.	8.2	130
57	Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology, 2011, 50, 1424-1430.	1.9	128
58	Elevated Serum BAFF Levels Are Associated With Rising Anti-Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus. Arthritis and Rheumatism, 2013, 65, 2672-2679.	6.7	128
59	Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology, 2013, 52, 2108-2115.	1.9	127
60	Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis and Rheumatism, 2012, 64, 3129-3138.	6.7	126
61	Predictors of lymphoma development in primary Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 1998, 28, 80-87.	3.4	124
62	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology, 2017, 56, 1227-1237.	1.9	124
63	Defining Clinical Improvement in Adult and Juvenile Myositis. Journal of Rheumatology, 2003, 30, 603-17.	2.0	124
64	Signal Transducer and Activator of Transcription-1 and Heat Shock Factor-1 Interact and Activate the Transcription of the Hsp-70 and Hsp-90 $\alpha$ Gene Promoters. Journal of Biological Chemistry, 1999, 274, 1723-1728.	3.4	122
65	New therapies for systemic lupus erythematosus – past imperfect, future tense. Nature Reviews Rheumatology, 2019, 15, 403-412.	8.0	122
66	Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology, 2012, 51, 491-498.	1.9	120
67	Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1543-1556.	6.7	119
68	Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Practice and Research in Clinical Rheumatology, 2009, 23, 469-480.	3.3	117
69	IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis and Rheumatism, 1999, 42, 631-640.	6.7	115
70	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 2013, 52, 1313-1322.	1.9	115
71	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.9	115
72	Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 3955-3965.	6.7	114

#	ARTICLE	IF	CITATIONS
73	Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 177, 7416-7422.	0.8	114
74	Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1984, 27, 132-138.	6.7	113
75	Genome-Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. <i>Arthritis and Rheumatism</i> , 2013, 65, 3239-3247.	6.7	113
76	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
77	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , 2006, 8, R13.	3.5	110
78	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013, 15, S2.	3.5	109
79	Utilization of the VH4-21 Gene Segment by Anti-DNA Antibodies from Patients with Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 1993, 6, 809-825.	6.5	107
80	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. <i>Arthritis Research and Therapy</i> , 2009, 11, R154.	3.5	107
81	AIDS virus infection and autoimmunity: A perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease. <i>Clinical Immunology and Immunopathology</i> , 1991, 58, 163-180.	2.0	106
82	Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. <i>Lancet, The</i> , 2013, 382, 809-818.	13.7	103
83	Rituximab in the treatment of inflammatory myopathies: a review. <i>Rheumatology</i> , 2017, 56, 26-36.	1.9	103
84	The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1988, 10, 231-249.	4.0	102
85	Inhibition of Caspase-3-mediated Poly(ADP-ribose) Polymerase (PARP) Apoptotic Cleavage by Human PARP Autoantibodies and Effect on Cells Undergoing Apoptosis. <i>Journal of Biological Chemistry</i> , 2000, 275, 9043-9046.	3.4	101
86	The 52 000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. <i>Immunology</i> , 2002, 106, 246-256.	4.4	101
87	Antibodies to apolipoprotein A-II, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 845-854.	6.7	100
88	The Origin, Sequence, Structure, and Consequences of Developing Anti-DNA Antibodies. <i>Arthritis and Rheumatism</i> , 1994, 37, 169-180.	6.7	98
89	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
90	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2004, 113, 1176-1187.	8.2	98

#	ARTICLE	IF	CITATIONS
91	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
92	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 4113-4119.	6.7	96
93	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006, 55, 892-899.	6.7	95
94	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971.	1.9	94
95	The diagnosis and management of the haematologic manifestations of lupus. <i>Journal of Autoimmunity</i> , 2016, 74, 139-160.	6.5	94
96	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006, 54, 3300-3305.	6.7	93
97	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 792-801.	0.9	92
98	The Association of Anti-Ro52 Autoantibodies with Myositis and Scleroderma Autoantibodies. <i>Journal of Autoimmunity</i> , 1999, 12, 137-142.	6.5	91
99	Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. <i>British Journal of Rheumatology</i> , 2003, 42, 230-234.	2.3	91
100	Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 55, 900-904.	6.7	91
101	Is $\gamma$ -actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. <i>Arthritis and Rheumatism</i> , 2004, 50, 866-870.	6.7	90
102	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
103	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
104	Overrepresentation of the Fc $\gamma$ receptor type IIA R131/R131 genotype in Caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1828-1832.	6.7	86
105	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 54-59.	0.9	86
106	Splenic involvement in rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 141-155.	3.4	85
107	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
108	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84



#	ARTICLE	IF	CITATIONS
109	Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. <i>European Journal of Immunology</i> , 1998, 28, 339-350.	2.9	83
110	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
111	Agalactosyl IgG: An aid to differential diagnosis in early synovitis. <i>Arthritis and Rheumatism</i> , 1991, 34, 1425-1429.	6.7	82
112	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. <i>Rheumatology</i> , 2011, 50, 1401-1408.	1.9	81
113	Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1343-1354.	6.7	80
114	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
115	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002, 29, 913-7.	2.0	80
116	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2004, 4, 398-402.	3.5	79
117	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , 2010, 49, 723-732.	1.9	79
118	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
119	Syndromes and complications of interferon therapy. <i>Current Opinion in Rheumatology</i> , 2007, 19, 61-66.	4.3	77
120	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , 2008, 58, 3593-3599.	6.7	76
121	Childhood- and adult-onset lupus: an update of similarities and differences. <i>Expert Review of Clinical Immunology</i> , 2009, 5, 391-403.	3.0	76
122	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
123	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , 2013, 52, 2292-2301.	1.9	72
124	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
125	TRIM21 and the Function of Antibodies inside Cells. <i>Trends in Immunology</i> , 2017, 38, 916-926.	6.8	70
126	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70



#	ARTICLE	IF	CITATIONS
127	Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. <i>Rheumatology</i> , 2012, 51, 476-481.	1.9	68
128	CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- $\gamma$ . <i>Frontiers in Immunology</i> , 2018, 9, 1372.	4.8	68
129	Diagnostic criteria for polymyositis and dermatomyositis. <i>Lancet</i> , The, 2003, 362, 1762-1763.	13.7	67
130	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. <i>Journal of Immunology</i> , 2010, 184, 6622-6628.	0.8	67
131	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of $\beta_2$ -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015, 54, 722-727.	1.9	67
132	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008, 58, 1784-1788.	6.7	66
133	Measuring IgA Anti- $\beta_2$ -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	2.5	66
134	Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. <i>Nature Reviews Rheumatology</i> , 2011, 7, 360-368.	8.0	65
135	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2021, 174, 1647-1657.	3.9	64
136	B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. <i>Rheumatology</i> , 2012, 51, 1208-1215.	1.9	63
137	Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome. <i>Rheumatology</i> , 2016, 55, 1548-1555.	1.9	63
138	Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. <i>Molecular Immunology</i> , 1996, 33, 471-483.	2.2	62
139	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 82-89.	5.8	62
140	B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. <i>Lancet Rheumatology</i> , The, 2020, 2, e589-e590.	3.9	62
141	B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 711-716.	8.0	61
142	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2015, 54, 2042-2050.	1.9	61
143	The use of alternative medical therapies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 1410-1418.	6.7	60
144	DNA-damaging autoantibodies and cancer: the lupus butterfly theory. <i>Nature Reviews Rheumatology</i> , 2016, 12, 429-434.	8.0	60

#	ARTICLE	IF	CITATIONS
145	Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1992, 5, 803-814.	6.5	59
146	Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2046-2055.	5.6	59
147	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 911-923.	5.6	59
148	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1835-1846.	5.6	59
149	Endorsement and memory bias of self-referential pain stimuli in depressed pain patients. <i>British Journal of Clinical Psychology</i> , 1995, 34, 267-277.	3.5	58
150	How do antiphospholipid antibodies bind $\beta$ 2-glycoprotein I?. <i>Arthritis and Rheumatism</i> , 2003, 48, 2111-2121.	6.7	58
151	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. <i>Arthritis and Rheumatism</i> , 2007, 57, 64-70.	6.7	58
152	Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. <i>Arthritis Care and Research</i> , 2016, 68, 981-987.	3.4	58
153	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1973-1979.	0.9	57
154	Analysis of B-cell epitopes of the Ro/SS-A autoantigen. <i>Trends in Immunology</i> , 1999, 20, 234-240.	7.5	56
155	A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. <i>Clinical Medicine</i> , 2014, 14, 157-164.	1.9	56
156	Global trends, potential mechanisms and early detection of organ damage in SLE. <i>Nature Reviews Rheumatology</i> , 2013, 9, 301-310.	8.0	55
157	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
158	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
159	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2273-2279.	2.0	54
160	Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. <i>Rheumatology</i> , 2010, 49, 1502-1504.	1.9	54
161	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	1.9	54
162	Human immunodeficiency virus infection in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 1168-1172.	6.7	52

#	ARTICLE	IF	CITATIONS
163	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	5.6	52
164	Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. <i>Lancet Rheumatology</i> , The, 2020, 2, e485-e496.	3.9	52
165	Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. <i>Journal of Autoimmunity</i> , 1990, 3, 393-414.	6.5	51
166	Biologic treatment in Sjogren's syndrome. <i>Rheumatology</i> , 2015, 54, 219-230.	1.9	51
167	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	2.7	51
168	Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. <i>European Journal of Immunology</i> , 2010, 40, 569-578.	2.9	50
169	Preferential secretion of a common anti-DNA idotype (16/6 Id) and anti-polynucleotide antibodies by normal mononuclear cells following stimulation with <i>Klebsiella pneumoniae</i> . <i>Immunology Letters</i> , 1986, 12, 313-319.	2.5	49
170	25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	3.4	49
171	Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. <i>Arthritis Care and Research</i> , 2017, 69, 857-866.	3.4	49
172	The role of the human anti-DNA idotype in autoimmunity. <i>Clinical Immunology and Immunopathology</i> , 1989, 51, 313-325.	2.0	48
173	Natural killer T cells in families of patients with systemic lupus erythematosus: Their possible role in regulation of IGG production. <i>Arthritis and Rheumatism</i> , 2007, 56, 303-310.	6.7	48
174	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
175	A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 1130-1135.	1.9	47
176	B cell depletion in autoimmune disease. <i>Arthritis Research</i> , 2003, 5, S17.	2.0	46
177	Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. <i>Rheumatology</i> , 2008, 48, 594-595.	1.9	46
178	Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2018, 154, 1432.	4.1	46
179	Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 2412-2423.	6.7	45
180	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , 2015, 2, e000104.	2.7	45

#	ARTICLE	IF	CITATIONS
181	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. <i>Cellular and Molecular Immunology</i> , 2018, 15, 158-170.	10.5	45
182	Imaging in CNS lupus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 727-739.	3.3	44
183	Mixed Connective Tissue Disease: Still Crazy After All These Years. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 421-436.	1.9	44
184	Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 291-302.	6.7	44
185	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. <i>Rheumatology</i> , 2010, 49, 392-394.	1.9	44
186	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , 2016, 1, .	11.9	44
187	Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: The response to splenectomy. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 20-25.	3.4	43
188	Pulmonary hypertension in autoimmune rheumatic diseases: Where are we now?. <i>Arthritis and Rheumatism</i> , 2002, 46, 1997-2009.	6.7	43
189	52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. <i>Arthritis Research and Therapy</i> , 2006, 8, R4.	3.5	43
190	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	1.9	43
191	Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1988, 1, 483-494.	6.5	42
192	Estimating Indirect Costs in Primary Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2010, 37, 1010-1015.	2.0	42
193	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
194	Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 237-264.	6.5	41
195	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
196	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1140-1142.	0.9	40
197	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
198	Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Glycobiology</i> , 2013, 23, 12-22.	2.5	39

#	ARTICLE	IF	CITATIONS
199	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	3.4	39
200	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
201	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021, 198, 213-221.	1.7	39
202	Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: A possible link between infection and lupus. <i>Human Antibodies</i> , 1995, 6, 52-56.	1.5	38
203	Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in caucasian patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999, 42, 2017-2018.	6.7	38
204	Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. <i>Clinical Rheumatology</i> , 2009, 28, 947-953.	2.2	38
205	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 133-139.	1.1	37
206	B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 146, 90-103.	3.2	37
207	The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. <i>Lupus Science and Medicine</i> , 2017, 4, e000182.	2.7	37
208	Post Hoc Analysis of the Phase II/III APRIL+SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLYS and APRIL. <i>Arthritis and Rheumatology</i> , 2017, 69, 122-130.	5.6	37
209	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
210	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , 2004, 31, 2390-4.	2.0	37
211	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
212	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
213	DNA antibody idiotypes: A review of their genetic, clinical, and immunopathologic features. <i>Seminars in Arthritis and Rheumatism</i> , 1987, 16, 245-252.	3.4	36
214	Immunoglobulin variable region sequences of human monoclonal anti-DNA, antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 141-154.	3.4	36
215	A systematic analysis of sequences of human antiphospholipid and anti-β <sub>2</sub> -glycoprotein I antibodies: The importance of somatic mutations and certain sequence motifs. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 246-265.	3.4	36
216	Common Patterns of B Cell Perturbation and Expanded V4-34 Immunoglobulin Gene Usage in Autoimmunity and Infection. <i>Autoimmunity</i> , 2004, 37, 9-15.	2.6	36

#	ARTICLE	IF	CITATIONS
217	The origin and significance of anti-DNA antibodies. Trends in Immunology, 1987, 8, 279-282.	7.5	35
218	Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients. Lancet, The, 1995, 345, 126.	13.7	35
219	Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. Arthritis and Rheumatism, 1998, 41, 918-926.	6.7	35
220	Numerical scoring for the Classic BILAG index. Rheumatology, 2009, 48, 1548-1552.	1.9	35
221	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open, 2019, 9, e032569.	1.9	35
222	Decreased live births in women with systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 1068-1072.	3.4	34
223	Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 75-85.	2.7	34
224	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
225	A common anti-DNA antibody idotype and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. Journal of Autoimmunity, 1989, 2, 803-811.	6.5	33
226	Elevated Levels of the 90 kD Heat Shock Protein in Patients with Systemic Lupus Erythematosus are Dependent upon Enhanced Transcription of the hsp90 $\alpha$ Gene. Journal of Autoimmunity, 1993, 6, 495-506.	6.5	33
227	Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. British Journal of Haematology, 2001, 113, 544-549.	2.5	33
228	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnology, 2006, 6, 8.	3.3	33
229	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care and Research, 2020, 72, 27-46.	3.4	33
230	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	1.9	33
231	Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. Journal of Autoimmunity, 1989, 2, 877-888.	6.5	32
232	Crossreactivity of Human Anti-dsDNA Antibodies to Phosphorylcholine: Clues to Their Origin. Journal of Autoimmunity, 2001, 16, 479-484.	6.5	32
233	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
234	Review: A Review of Serological Abnormalities in Relatives of SLE Patients. Lupus, 1993, 2, 145-150.	1.6	30



#	ARTICLE	IF	CITATIONS
235	Bcl-2 and Fas, Molecules Which Influence Apoptosis. A Possible Role in Systemic Lupus Erythematosus?. Autoimmunity, 1994, 17, 271-278.	2.6	30
236	Apoptosis in Human Autoimmune Diseases. International Reviews of Immunology, 1999, 18, 563-589.	3.3	30
237	Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens. Journal of Immunology, 2006, 177, 1729-1736.	0.8	30
238	Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: New aspects. Best Practice and Research in Clinical Rheumatology, 2013, 27, 309-318.	3.3	30
239	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
240	HLA Association of Anti-Ro60 and Anti-Ro52 Antibodies in Sjögren's Syndrome. Journal of Autoimmunity, 1994, 7, 611-621.	6.5	29
241	The importance of somatic mutations in the V $\lambda$ gene 2a2 in human monoclonal anti-DNA antibodies. Journal of Molecular Biology, 2001, 307, 149-160.	4.2	29
242	Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?. Lupus, 2004, 13, 881-885.	1.6	29
243	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology, 2010, 49, 691-696.	1.9	29
244	Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Design, Development and Therapy, 2015, 9, 1331.	4.3	29
245	&lt;p&gt;Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?&lt;/p&gt;. ImmunoTargets and Therapy, 2020, Volume 9, 105-110.	5.8	29
246	Autoantibody Repertoire to Ro/SSA and La/SSB Antigens in Patients with Primary and Secondary Sjögren's syndrome. Journal of Autoimmunity, 1996, 9, 537-544.	6.5	28
247	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. Journal of Rheumatology, 2014, 41, 875-880.	2.0	28
248	Pancreatic disease in the autoimmune rheumatic disorders. Seminars in Arthritis and Rheumatism, 1989, 19, 158-165.	3.4	27
249	Systemic lupus erythematosus"2005 annus mirabilis?. Nature Clinical Practice Rheumatology, 2006, 2, 145-152.	3.2	27
250	B-cell survival factors in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 122-151.	2.7	27
251	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
252	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27



#	ARTICLE	IF	CITATIONS
253	Elevation of IL-6 in Transgenic Mice Results in Increased Levels of the 90kDa Heat Shock Protein (hsp90) and the Production of Anti-hsp90 Antibodies. <i>Journal of Autoimmunity</i> , 1998, 11, 249-253.	6.5	26
254	Systemic Lupus International Collaborating Group's "onwards and upwards?". <i>Lupus</i> , 2006, 15, 606-607.	1.6	26
255	Primary Sjögren's syndrome activity and damage indices comparison. <i>European Journal of Clinical Investigation</i> , 2010, 40, 636-644.	3.4	26
256	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
257	Pathology of Systemic Lupus Erythematosus: The Challenges Ahead. <i>Methods in Molecular Biology</i> , 2014, 1134, 1-16.	0.9	26
258	Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; SDI). <i>Arthritis and Rheumatism</i> , 2003, 49, S225-S233.	6.7	25
259	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. <i>Molecular Immunology</i> , 2003, 40, 49-60.	2.2	25
260	Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. <i>European Journal of Internal Medicine</i> , 2004, 15, 162-167.	2.2	25
261	Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Rheumatology</i> , 2013, 52, 951-952.	1.9	25
262	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
263	"Mixed connective tissue disease": a condition in search of an identity. <i>Clinical and Experimental Medicine</i> , 2020, 20, 159-166.	3.6	25
264	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , 2021, 17, 11-15.	8.0	25
265	Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2021, 73, 1626-1637.	5.6	25
266	The regulation of heat shock proteins and their role in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 155-162.	3.4	24
267	Immunisation of patients with systemic lupus erythematosus: the current state of play. <i>Lupus</i> , 1999, 8, 497-501.	1.6	24
268	Vaccines and biologics: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1446-1454.	0.9	24
269	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 93, 114-123.	6.5	24
270	Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. <i>Scientific Reports</i> , 2019, 9, 15502.	3.3	24

#	ARTICLE	IF	CITATIONS
271	&lt;p>Towards Precision Medicine in Systemic Lupus Erythematosus&/p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 39-49.	0.7	24
272	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology, 2021, 60, 4558-4567.	1.9	24
273	The Role of Hsp90 in Sle. Autoimmunity, 1994, 19, 211-218.	2.6	23
274	Myositis overlap syndromes. Current Opinion in Rheumatology, 1999, 11, 468-474.	4.3	23
275	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology, 2008, 48, 573-575.	1.9	23
276	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Research and Therapy, 2015, 17, 26.	3.5	23
277	Mixed connective tissue disease's enigma variations?. Rheumatology, 2017, 56, kew265.	1.9	23
278	An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opinion on Pharmacotherapy, 2018, 19, 1613-1621.	1.8	23
279	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
280	Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. EBioMedicine, 2021, 65, 103243.	6.1	23
281	The endocrinologic associations of the autoimmune rheumatic diseases. Seminars in Arthritis and Rheumatism, 1987, 17, 58-70.	3.4	22
282	Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. Current Opinion in Immunology, 1991, 3, 930-935.	5.5	22
283	1 Immunopathogenesis of SLE. Bailliere's Clinical Rheumatology, 1998, 12, 385-403.	1.0	22
284	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Research, 2005, 7, R47.	2.0	22
285	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 72-78.	3.4	22
286	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. Journal of Dermatological Science, 2013, 71, 22-28.	1.9	22
287	Why and how should we measure disease activity and damage in lupus?. Presse Medicale, 2014, 43, e151-e156.	1.9	22
288	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology, 2015, 54, 1050-1055.	1.9	22

#	ARTICLE	IF	CITATIONS
289	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. Rheumatology, 2015, 54, 655-659.	1.9	22
290	Why, why, why de-lupus (does so badly in clinical trials). Expert Review of Clinical Immunology, 2016, 12, 95-98.	3.0	22
291	Musculoskeletal complications of haematological disease. Rheumatology, 2016, 55, 968-981.	1.9	22
292	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
293	B cell targeted therapies in autoimmune diseases. Journal of rheumatology Supplement, The, 2006, 77, 24-8.	2.2	22
294	B Lymphocyte Hyperactivity in Families of Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 1996, 9, 59-65.	6.5	21
295	Interrater reliability and aspects of validity of the myositis damage index. Annals of the Rheumatic Diseases, 2011, 70, 1272-1276.	0.9	21
296	The coming of age of adolescent rheumatology. Nature Reviews Rheumatology, 2014, 10, 187-193.	8.0	21
297	Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology, 2015, 54, 1403-1407.	1.9	21
298	Advances in the treatment of ocular dryness associated with Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 2015, 45, 321-327.	3.4	21
299	Longer duration of B cell depletion is associated with better outcome. Rheumatology, 2015, 54, 1876-1881.	1.9	21
300	From BILAG to BILAG-based combined lupus assessment—30 years on. Rheumatology, 2016, 55, 1357-1363.	1.9	21
301	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
302	Comparison of Three Classification Criteria Sets for Systemic Lupus Erythematosus: A Study Looking at Links to Outcome and Mortality. Arthritis Care and Research, 2020, 72, 1611-1614.	3.4	21
303	Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2013, 31, 896-903.	0.8	21
304	The role of antigen in autoimmune responses with special reference to changes in carbohydrate structure of IgG in rheumatoid arthritis. Journal of Autoimmunity, 1988, 1, 499-506.	6.5	20
305	Belimumab in systemic lupus erythematosus. RMD Open, 2015, 1, e000011-e000011.	3.8	20
306	Molecular Cloning and Expression of the Fabs of Human Autoantibodies in Escherichia coli. Journal of Biological Chemistry, 2000, 275, 35129-35136.	3.4	19

#	ARTICLE	IF	CITATIONS
307	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. <i>Journal of Immunology</i> , 2009, 182, 4836-4843.	0.8	19
308	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. <i>Blood</i> , 2014, 124, 3808-3816.	1.4	19
309	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , 2020, 59, 524-533.	1.9	19
310	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 940-952.	1.9	19
311	Idiotypes and autoimmunity: a review of their role in human disease. <i>Journal of Autoimmunity</i> , 1988, 1, 7-30.	6.5	18
312	DNA Antibody Idiotypes: An Analysis of Their Clinical Connections and Origins. <i>International Reviews of Immunology</i> , 1990, 5, 279-293.	3.3	18
313	Cross-Reaction of Lupus Anti-dsDNA Antibodies with Protein Translation Factor EF-2. <i>Clinical Immunology</i> , 2001, 98, 293-300.	3.2	18
314	Expression of the Fabs of human auto-antibodies in <i>Escherichia coli</i> : optimization and determination of their fine binding characteristics and cross-reactivity. <i>Journal of Molecular Biology</i> , 2001, 308, 527-539.	4.2	18
315	Screening Autoantibody Profiles in Systemic Rheumatic Disease with a Diagnostic Protein Microarray That Uses a Filtration-Assisted Nanodot Array Luminometric Immunoassay (NALIA). <i>Clinical Chemistry</i> , 2008, 54, 883-890.	3.2	18
316	Autoantibodies against C1q as a Diagnostic Measure of Lupus Nephritis: Systematic Review and Meta-analysis. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2014, 05, 210.	1.5	18
317	A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. <i>Rheumatology</i> , 2020, 59, 2734-2745.	1.9	18
318	Sjögren's Syndrome. <i>Drugs and Aging</i> , 2008, 25, 19-33.	2.7	17
319	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	1.9	17
320	Rituximab—it was the best of times, it was the worst of times. <i>Autoimmunity Reviews</i> , 2012, 11, 790-791.	5.8	17
321	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e90-e90.	0.9	17
322	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
323	Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 58, 1116-1124.	6.7	16
324	Evaluating the conformation of recombinant domain I of $\beta$ 2-glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , 2011, 49, 56-63.	2.2	16

#	ARTICLE	IF	CITATIONS
325	Rituximab: the Lupus Journey. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 30-41.	1.4	16
326	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015, 17, 47.	3.5	16
327	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	3.0	16
328	Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 382-387.	1.9	16
329	Rituximab – The first twenty years. <i>Lupus</i> , 2021, 30, 371-377.	1.6	16
330	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For musculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	1.9	16
331	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. <i>Molecular Immunology</i> , 2004, 40, 745-758.	2.2	15
332	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3512-3521.	6.7	15
333	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018, 57, 125-133.	1.9	15
334	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
335	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , 2019, 9, e028697.	1.9	15
336	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 299-309.	1.4	15
337	Why do patients with myositis die? A retrospective analysis of a single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 820-826.	0.8	15
338	Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. <i>Seminars in Arthritis and Rheumatism</i> , 1996, 26, 515-525.	3.4	14
339	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. <i>Arthritis Research and Therapy</i> , 2005, 7, R971.	3.5	14
340	Treating patients with lupus with B-cell depletion. <i>Lupus</i> , 2008, 17, 400-404.	1.6	14
341	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 31-41.	4.1	14
342	Impaired C3b/iC3b deposition on <i>Streptococcus pneumoniae</i> in serum from patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2009, 48, 1498-1501.	1.9	14

#	ARTICLE	IF	CITATIONS
343	Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. <i>International Immunology</i> , 2010, 22, 359-366.	4.0	14
344	A negatively charged domain of LAT mediates its interaction with the active form of Lck. <i>Molecular Membrane Biology</i> , 2011, 28, 487-494.	2.0	14
345	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 667-676.	3.0	14
346	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	4.8	14
347	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e000885.	3.8	14
348	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020, 59, 146-152.	1.9	14
349	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
350	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. <i>Rheumatology</i> , 2022, 61, 4006-4015.	1.9	14
351	Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 989-991.	0.9	13
352	Assessment of patients with primary Sjogren's syndrome--outcome over 10 years using the Sjogren's Syndrome Damage Index. <i>Rheumatology</i> , 2010, 49, 1559-1562.	1.9	13
353	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012, 51, 2099-2105.	1.9	13
354	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 311-326.	3.1	13
355	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 427-438.	2.7	13
356	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
357	Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. <i>Lupus</i> , 2021, 30, 702-706.	1.6	13
358	THE USE OF HYBRIDOMAS TO ANALYSE AUTOIMMUNITY. <i>British Medical Bulletin</i> , 1984, 40, 262-266.	6.9	12
359	Biological treatments for systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 187-191.	1.1	12
360	The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 377-385.	3.0	12

#	ARTICLE	IF	CITATIONS
361	Agrin Signalling Contributes to Cell Activation and Is Overexpressed in T Lymphocytes from Lupus Patients. <i>Journal of Immunology</i> , 2007, 179, 7975-7983.	0.8	12
362	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 2392-2401.	6.7	12
363	Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 563-574.	3.3	12
364	The Systemic Lupus International Collaborating Clinics (SLICC) group â€“ It was 20 years ago today. <i>Lupus</i> , 2011, 20, 1426-1432.	1.6	12
365	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	1.9	12
366	Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. <i>BMC Rheumatology</i> , 2019, 3, 32.	1.6	12
367	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
368	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 639-647.	3.1	12
369	What Does it Mean to be a British Isles Lupus Assessment Groupâ€™Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. <i>Arthritis and Rheumatology</i> , 2021, 73, 2059-2068.	5.6	12
370	Differential levels of IFNÎ± subtypes in autoimmunity and viral infection. <i>Cytokine</i> , 2021, 144, 155533.	3.2	12
371	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
372	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
373	Spontaneous antibody-secreting cells against DNA and common environmental antigens in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1990, 3, 523-530.	6.5	11
374	Autoantibodies: Markers of Disease or Pathogenic?. <i>Annals of the New York Academy of Sciences</i> , 1997, 823, 256-262.	3.8	11
375	Systemic lupus erythematosus and Sjögren's syndrome: Historical perspective and ongoing concerns. <i>Arthritis and Rheumatism</i> , 2004, 50, 681-683.	6.7	11
376	Current pharmacological treatment of idiopathic inflammatory myopathies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 547-558.	3.1	11
377	Advances in systemic lupus erythematosus. <i>Medicine</i> , 2018, 46, 84-92.	0.4	11
378	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11



#	ARTICLE	IF	CITATIONS
379	Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. <i>Rheumatology</i> , 2020, 59, 194-204.	1.9	11
380	Assessing outcomes in a lupus nephritis cohort over a 40-year period. <i>Rheumatology</i> , 2021, 60, 1814-1822.	1.9	11
381	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021, 60, 1376-1386.	1.9	11
382	Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. <i>Rheumatology</i> , 2021, 60, 5620-5629.	1.9	11
383	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5379-5389.	1.9	11
384	The rheumatologic complications of hematologic disorders. <i>Seminars in Arthritis and Rheumatism</i> , 1983, 12, 348-358.	3.4	10
385	Comparison of a Monoclonal and Polyclonal Anti-idiotypic Against a Human IgG Anti-DNA Antibody. <i>Journal of Autoimmunity</i> , 1994, 7, 349-367.	6.5	10
386	Naming names! Comment on the article by Smolen and Steiner. <i>Arthritis and Rheumatism</i> , 1999, 42, 191-193.	6.7	10
387	BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM & . Thank you MAM. <i>Lupus</i> , 2007, 16, 849-851.	1.6	10
388	Lupus nephritis: assessing the evidence, considering the future. <i>Lupus</i> , 2007, 16, 210-211.	1.6	10
389	Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , 2014, 10, 71-72.	8.0	10
390	Present and novel biologic drugs in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 167-174.	0.8	10
391	An Analysis of Autoimmunity through Studies of DNA Antibody Idiotypes. <i>Autoimmunity</i> , 1988, 1, 67-75.	2.6	9
392	Interleukin-10 promoter polymorphism and lupus nephritis: Comment on the article by Mok et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 590-591.	6.7	9
393	Treatment of rheumatoid arthritis is good medicine. <i>BMJ: British Medical Journal</i> , 2011, 343, d6962-d6962.	2.3	9
394	Meryl Streep and the problems of clinical trials. <i>Arthritis Research and Therapy</i> , 2012, 14, 113.	3.5	9
395	B-Lymphocyte Signalling Abnormalities and Lupus Immunopathology. <i>International Reviews of Immunology</i> , 2013, 32, 428-444.	3.3	9
396	Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 837-848.	3.0	9

#	ARTICLE	IF	CITATIONS
397	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2015, 55, kev373.	1.9	9
398	Low Percentage of Signal Regulatory Protein $\beta$ 2+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2018, 9, 2865.	4.8	9
399	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
400	Outcomes of membranous and proliferative lupus nephritis â€ analysis of a single-centre cohort with more than 30 years of follow-up. <i>Rheumatology</i> , 2020, 59, 3314-3323.	1.9	9
401	Anti-IFN $\gamma$ R Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 519-528.	3.1	9
402	Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?. <i>Rheumatology</i> , 2022, 61, 2894-2904.	1.9	9
403	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
404	Thirty years, five hundred patients: some lessons learned from running a lupus clinic. <i>Lupus</i> , 2010, 19, 667-674.	1.6	8
405	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
406	Biologic therapies for systemic lupus erythematosus: where are we now?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 597-608.	4.3	8
407	Transcription of the Genes Encoding the Small Heat Shock Protein Ubiquitin is Unchanged in Patients with Systemic Lupus Erythematosus. <i>Autoimmunity</i> , 1992, 13, 197-200.	2.6	7
408	Elevated Levels of the 70 kD Heat Shock Protein in Patients with Systemic Lupus Erythematosus are not Dependent on Enhanced Transcription of the hsp70 Gene. <i>Lupus</i> , 1993, 2, 297-301.	1.6	7
409	Autoantibodies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 1994, 6, 468-473.	4.3	7
410	Idiotypic Manipulation for Autoimmune Diseases: Where Are We Going?. <i>Autoimmunity</i> , 1996, 24, 55-63.	2.6	7
411	Structureâ€function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , 1999, 1, 1-28.	3.9	7
412	Anti-cardiolipin/ $\beta$ 2-2 glycoprotein activities co-exist on human anti-DNA antibody light chains. <i>Molecular Immunology</i> , 2003, 40, 517-530.	2.2	7
413	Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. <i>Immunology</i> , 2005, 114, 418-427.	4.4	7
414	SLE-associated arthropathy: truly a benign entity?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 695-696.	8.0	7

#	ARTICLE	IF	CITATIONS
415	Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. <i>European Journal of Clinical Investigation</i> , 2013, 43, 866-880.	3.4	7
416	The safety of pharmacological treatment options for lupus nephritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1041-1054.	2.4	7
417	Kidney disease in primary anti-phospholipid antibody syndrome. <i>Rheumatology</i> , 2017, 56, kew307.	1.9	7
418	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by IgG From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017, 7, 10788.	3.3	7
419	Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. <i>Clinical Rheumatology</i> , 2018, 37, 2399-2404.	2.2	7
420	Fracture risk in systemic lupus erythematosus patients over 28 years. <i>Rheumatology</i> , 2021, 60, 2765-2772.	1.9	7
421	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , 2020, 59, 1489-1494.	1.9	7
422	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
423	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
424	Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 601-605.	0.8	7
425	Sequence analysis and fine specificity of two human monoclonal antibodies to histone H1. <i>Molecular Immunology</i> , 1994, 31, 269-277.	2.2	6
426	Assessment of inflammatory myositis. <i>Current Opinion in Rheumatology</i> , 2001, 13, 488-492.	4.3	6
427	Rhubarb and Reliability – A Jane Austen View of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 7-8.	2.0	6
428	Towards treating lupus nephritis without oral steroids: a dream-come-true?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1271-1272.	0.9	6
429	Advances in systemic lupus erythematosus. <i>Medicine</i> , 2014, 42, 126-133.	0.4	6
430	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	4.6	6
431	Analysis of factors affecting human hybridoma production. <i>Human Antibodies</i> , 1990, 1, 160-165.	1.5	5
432	p185, an Immunodominant Epitope, Is an Autoantigen Mimotope. <i>Journal of Biological Chemistry</i> , 2011, 286, 26220-26227.	3.4	5

#	ARTICLE	IF	CITATIONS
433	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , 2014, 1, e000013.	2.7	5
434	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. <i>Current Rheumatology Reports</i> , 2017, 19, 50.	4.7	5
435	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 259-261.	3.8	5
436	Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 262-266.	0.8	5
437	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 133-139.	1.1	5
438	Prevalence of Ro (SS-A) antibodies in patients with polymyositis. <i>Arthritis and Rheumatism</i> , 1987, 30, 1320-1320.	6.7	4
439	Fine binding characteristics of human autoantibodiesâ€”partial molecular characterization. <i>Molecular Immunology</i> , 2004, 41, 495-510.	2.2	4
440	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, R48.	3.5	4
441	A case of repetitive myocardial infarction with unobstructed coronaries due to Churgâ€™Strauss syndrome. <i>European Heart Journal - Case Reports</i> , 2019, 3, .	0.6	4
442	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes. , 2019, , 355-365.		4
443	Can we predict if patients with SLE will require more than one cycle of rituximab?. <i>Rheumatology</i> , 2022, 61, 1892-1899.	1.9	4
444	The Expression of Heat Shock Proteins in Systemic Lupus Erythematosus. , 1994, , 99-129.		4
445	Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. <i>Rheumatology</i> , 2022, 62, 200-208.	1.9	4
446	Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 62, 225-233.	1.9	4
447	Does Mitogen-Induced Antibody Production by Normal Blood Cells Mimic Spontaneous Production in Lupus?. <i>Autoimmunity</i> , 1992, 13, 285-290.	2.6	3
448	Enhanced Transcription of the Gene Encoding the Smn Autoantigen in Patients with Systemic Lupus Erythematosus Does not Result in Enhanced Levels of the SMN Protein. <i>Autoimmunity</i> , 1994, 19, 81-87.	2.6	3
449	Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. <i>Bailliere's Clinical Rheumatology</i> , 1996, 10, 333-347.	1.0	3
450	The role of in vitro expression systems in the investigation of antibodies to DNA. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 130-139.	3.4	3

#	ARTICLE	IF	CITATIONS
451	Optimisation of herpes simplex virus-based vectors for delivery to human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2002, 270, 235-246.	1.4	3
452	Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody. <i>Molecular Immunology</i> , 2005, 42, 39-48.	2.2	3
453	Inflammatory muscle disease assessment. <i>Current Rheumatology Reports</i> , 2008, 10, 328-332.	4.7	3
454	What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1093-1107.	3.0	3
455	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. <i>ACR Open Rheumatology</i> , 2019, 1, 145-155.	2.1	3
456	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	3.9	3
457	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 4185-4198.	1.9	3
458	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
459	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
460	Rivaroxaban Limits Complement Activation Compared to Warfarin in Antiphospholipid Syndrome Patients with Venous Thromboembolism. <i>Blood</i> , 2015, 126, 2328-2328.	1.4	3
461	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis. <i>Kidney International Reports</i> , 2022, 7, 841-847.	0.8	3
462	Review of major endocrine abnormalities in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 791-796.	0.8	3
463	Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia® Analysers and Three Thrombin Generation Methods, in APS and SLE Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 69.	2.4	3
464	ASessment of Common Idiotypic PR4-Id in Serial Bleeds from Lupus Patients. <i>Autoimmunity</i> , 1991, 9, 7-12.	2.6	2
465	Autoimmune rheumatic diseases and the heart. <i>British Journal of Hospital Medicine</i> , 1999, 60, 95-99.	0.2	2
466	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies. , 2006, , 470-491.		2
467	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , 2008, 59, 1197-1198.	6.7	2
468	B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus. <i>Future Rheumatology</i> , 2008, 3, 59-68.	0.2	2

#	ARTICLE	IF	CITATIONS
469	Reprint of: B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 148, 344-358.	3.2	2
470	Pathogenesis of neurocognitive and neuropsychiatric manifestations in childhood-onset lupus: an overview. <i>Rheumatology Reports</i> , 2013, 5, 6.	0.1	2
471	A3.27â€¦Effect of rituximab on different isotypes of serum immunoglobulins in patients with SLE. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A53.1-A53.	0.9	2
472	Clinical Trials Perception in Rheumatology Patients: Experience from a Single Rheumatology Tertiary Center. <i>Journal of Rheumatology</i> , 2015, 42, 988-993.	2.0	2
473	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	1.9	2
474	Very delayed lupus nephritis: a report of three cases and literature review. <i>Lupus Science and Medicine</i> , 2018, 5, e000241.	2.7	2
475	Systemic lupus erythematosus: causes and manifestations. <i>Trends in Urology &amp; Men's Health</i> , 2020, 11, 26-29.	0.4	2
476	Abnormalities in the Glycosylation of IgG and its Clinical Utility. <i>Advances in Experimental Medicine and Biology</i> , 1995, 376, 179-183.	1.6	2
477	The Pathophysiology of Antiphospholipid Syndrome. <i>The Open Urology &amp; Nephrology Journal</i> , 2015, 8, 2-9.	0.2	2
478	Use of autologous stem cell transplantation in adult patients with idiopathic inflammatory myopathies: a case-report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 979.	0.8	2
479	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2
480	Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period. <i>Rheumatology</i> , 2022, 62, 209-216.	1.9	2
481	P243â€¦Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, .	1.9	2
482	Adverse events of treatment with rituximab in patients with myositis. <i>Rheumatology</i> , 2023, 62, e16-e17.	1.9	2
483	Multispecific monoclonal antibodies. <i>Trends in Immunology</i> , 1986, 7, 354-355.	7.5	1
484	Glycosylation of Immunoglobulins. <i>BioDrugs</i> , 1994, 1, 169-172.	0.7	1
485	Immunological aspects. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 215-229.	1.0	1
486	The clinical relevance of antibodies to ribosomal Pâ€”where are we now?. <i>Japanese Journal of Rheumatology</i> , 1997, 7, 235-245.	0.0	1

#	ARTICLE	IF	CITATIONS
487	Assessing lupus. Arthritis and Rheumatism, 1998, 41, 2276-2276.	6.7	1
488	Cyclophosphamide: Time to Say Goodnight and Goodbye?. Current Rheumatology Reviews, 2005, 1, 189-191.	0.8	1
489	Autoimmune rheumatic diseases: an introduction. Medicine, 2006, 34, 439-440.	0.4	1
490	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2006, 54, 2343-2344.	6.7	1
491	mAbs in nonlupus autoimmune rheumatic disease. Current Opinion in Hematology, 2009, 16, 280-284.	2.5	1
492	Dr. Eisenberg replies. Journal of Rheumatology, 2013, 40, 734.1-734.	2.0	1
493	Is the age of eponymous diseases in rheumatology over?. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314,rgBT /Over	0.5	1
494	Overview of biologic therapies in autoimmune rheumatic diseases. Medicine, 2014, 42, 184-187.	0.4	1
495	A8.13â€¦Changes in the relationship between BAFF, BAFF-R and B cell phenotype following rituximab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, A81.1-A81.	0.9	1
496	Asymmetric appearance of immunological abnormalities in close relatives of patients with systemic lupus erythematosus. Clinical Immunology, 2015, 157, 226-227.	3.2	1
497	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
498	324.â€¦LUPUS AND AVASCULAR NECROSIS OF THE BONE: HAS THE INCIDENCE IMPROVED?. Rheumatology, 2017, 56, .	1.9	1
499	E050â€¦Adverse infusion reactions to rituximab in myositis: a retrospective analysis. Rheumatology, 2019, 58, .	1.9	1
500	E083â€¦Designing a diet interventional study for autoimmune rheumatic disease: asking patients what they think. Rheumatology, 2019, 58, .	1.9	1
501	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Frontiers in Immunology, 2020, 11, 592639.	4.8	1
502	IgG vs IgG + IgM antiâ€¦double stranded DNA measurement: a comparative report for clinical practice. Rheumatology, 2021, 60, 3951-3952.	1.9	1
503	Systemic Lupus Erythematosus: Direct B-Cell Blocking. Milestones in Drug Therapy, 2014, , 65-78.	0.1	1
504	Immunopathogenesis of systemic lupus erythematosus. Future Rheumatology, 2007, 2, 93-103.	0.2	1



#	ARTICLE	IF	CITATIONS
505	The role of biologicals in the treatment of lupus nephritis. , 2012, , 69-78.		1
506	Idiotypes of DNA-Binding Autoantibodies:Mapping by Epitope Scanning and Molecular Modelling. , 1994, , 173-189.		1
507	Advances in systemic lupus erythematosus. Medicine, 2021, , .	0.4	1
508	Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis. Clinical and Experimental Rheumatology, 2021, 39, 601-605.	0.8	1
509	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	1
510	Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations. Frontiers in Medicine, 2022, 9, .	2.6	1
511	COMMUNICATION CHANNELS OF THE ARTHRITIS AND RHEUMATISM COUNCILâ€”THE ROLE OF THE HONORARY MEDICAL SECRETARIES. Rheumatology, 1993, 32, 947-948.	1.9	0
512	The clinical relevance of antibodies to ribosomal Pâ€”where are we now?. Japanese Journal of Rheumatology, 1997, 7, 235-245.	0.0	0
513	Use of Phage Expression to Analyze Regions of a Human V4-34(VH4-21)-encoded IgG Autoantibody Required for Recognition of DNA No Involvement of the 9G4 Idiotope. Annals of the New York Academy of Sciences, 1997, 815, 338-341.	3.8	0
514	Autoantibodies in Systemic Lupus Erythematosus. , 1999, , 156-162.		0
515	Sequence features of monoclonal antiphospholipid antibodies: Comment on the article by Ikematsu et al. Arthritis and Rheumatism, 1999, 42, 1783-1784.	6.7	0
516	What's new in â€” Autoimmune rheumatic diseases. Medicine, 2002, 30, 1-4.	0.4	0
517	Relative Importance of Different Human aPL Derived Heavy and Light Chains in the Binding of aPL to Cardiolipin. Clinical Science, 2003, 104, 47P-47P.	0.0	0
518	Fine binding characteristics of human autoantibodies?partial molecular characterization. Molecular Immunology, 2004, 41, 495-495.	2.2	0
519	Making sure the treatment of myositis does not get â€”lost in translationâ€” Current Opinion in Rheumatology, 2004, 16, 665-667.	4.3	0
520	Inflammatory Muscle Diseases: Pathogenesis and Clinical Features. Handbook of Systemic Autoimmune Diseases, 2004, 3, 107-128.	0.1	0
521	Autoimmune diseases. Medicine, 2008, 36, 279-283.	0.4	0
522	Introduction to a systemic lupus erythematosus â€” biomarkers meeting held at University College London on 23rd and 24th February 2007. Lupus, 2008, 17, 231-231.	1.6	0

#	ARTICLE	IF	CITATIONS
523	Chapter 15 Systemic Lupus Erythematosus and Endocrine Disorders. Handbook of Systemic Autoimmune Diseases, 2008, 9, 173-184.	0.1	0
524	Therapeutic potential (1). Lupus, 2008, 17, 259-261.	1.6	0
525	Conversion of discoid lupus to antiphospholipid syndrome and SLE. Nature Clinical Practice Rheumatology, 2008, 4, 106-110.	3.2	0
526	Rheumatology: introduction. Medicine, 2010, 38, 125.	0.4	0
527	“Muscles and bones” Arthritis and Rheumatism, 2010, 62, 2616-2618.	6.7	0
528	Working through the recession. Rheumatology, 2010, 49, 1613-1615.	1.9	0
529	Concurrent oral 4 - Connective tissue disease: OP22. B Cell Numbers and Phenotype at Clinical Relapse Following Rituximab Therapy Differ in SLE Patients According to Anti-Dsdna Antibody Titres. Rheumatology, 2011, 50, iii40-iii42.	1.9	0
530	Recent advances in the treatment of systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2014, 9, 89-100.	0.3	0
531	Rheumatology: introduction. Medicine, 2014, 42, 189.	0.4	0
532	A retrospective study of long-term outcomes in 152 patients with primary Sjögren’s syndrome: 25-year experience. Clinical Medicine, 2014, 14, 322.	1.9	0
533	Systemic lupus erythematosus and the role of the GP. The Prescriber, 2015, 26, 31-35.	0.3	0
534	296. A Study of the Influence of Ethnicity on Serology and Clinical Features in Lupus. Rheumatology, 0, , .	1.9	0
535	294. The Challenge of Achieving Complete Remission: A 32-Year Retrospective Analysis of a Lupus Cohort. Rheumatology, 0, , .	1.9	0
536	Thrombocytopenia in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 121-130.	0.1	0
537	Comment on: Musculoskeletal complication of haematological disease: Reply. Rheumatology, 2017, 56, 321-321.	1.9	0
538	Obituary for Paul Bacon. Rheumatology, 2018, 57, 943-945.	1.9	0
539	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
540	O37. Complex immunophenotyping stratifies patients with primary and secondary Sjögren’s syndrome into distinct clinically relevant groups with potential therapeutic implications. Rheumatology, 2018, 57, .	1.9	0

#	ARTICLE	IF	CITATIONS
541	138â€fDisease trends and phenotypes among different age groups: a study in lupus. Rheumatology, 2018, 57, .	1.9	0
542	123â€fAnatomy of a Sj�gren���s cohort: clinical features and outcome of the University College Hospital Sj�gren���s Cohort (1986-2016) utilising the EULAR Sj�gren's syndrome disease activity index score. Rheumatology, 2018, 57, .	1.9	0
543	i052��fThe long-term prospects for non-fatal systemic lupus erythematosus. Rheumatology, 2018, 57, .	1.9	0
544	E088��fAntiphospholipase A2 receptor antibodies, a marker of idiopathic membranous nephropathy, are not present in membranous lupus nephritis. Rheumatology, 2019, 58, .	1.9	0
545	239��fWhy do some patients with systemic lupus erythematosus fail to respond to B cell depletion using rituximab?. Rheumatology, 2019, 58, .	1.9	0
546	242��fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
547	238��fDoes the new (preliminary) American College of Rheumatology/European League Against Rheumatism classification criteria set provide prognostic information about the outcome in systemic lupus erythematosus?. Rheumatology, 2019, 58, .	1.9	0
548	Recognition and management of systemic lupus erythematosus. The Prescriber, 2019, 30, 13-20.	0.3	0
549	FRI0174��...SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJ�-GREN���S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL. , 2019, , .		0
550	Comment on: ���Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab��� by Eric Morand <i>et al</i>. Annals of the Rheumatic Diseases, 2019, 78, e121-e121.	0.9	0
551	P170��fPredictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. Rheumatology, 2020, 59, .	1.9	0
552	P122��...What do patients with lupus and Sj�gren���s syndrome know about cardiovascular risk?. , 2020, , .		0
553	P36��...Using machine learning to identify and stratify patients with juvenile-onset SLE. , 2020, , .		0
554	P59��...Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. , 2020, , .		0
555	P162��...Progression of subclinical cardiovascular disease in SLE: a five year follow up study. , 2020, , .		0
556	P171��...Cardiovascular risk in young patients with lupus: investigating metabolic biomarkers and the immunological phenotype. , 2020, , .		0
557	P21��...Investigation of possible pathogenic autoantibodies in membranous lupus nephritis. , 2020, , .		0
558	P42��...Disease activity, impaired iron transport and failed sequestration: a novel mechanism for anaemia in systemic lupus erythematosus. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
559	Eric Bywaters a life story: 1 June 1910 to 2 April 2003. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 996-998.	0.9	0
560	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. <i>Rheumatology</i> , 2021, 60, .	1.9	0
561	CRESS: improving the assessment of disease activity in Sjögren's syndrome. <i>Lancet Rheumatology</i> , The, 2021, 3, e534-e535.	3.9	0
562	Autoimmunity “ Systemic Lupus Erythematosus. , 2005, , 505-514.		0
563	Systemic Lupus Erythematosus, Autoantibodies. , 2014, , 1141-1150.		0
564	Myositis. <i>Contemporary Clinical Neuroscience</i> , 2019, , 787-808.	0.3	0
565	Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
566	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.8	0
567	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 214-218.	0.8	0
568	FC055: Effect of Atacicept on Renal Function in SLE Patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
569	The BILAG-2004 index is associated with development of new damage in SLE. <i>Rheumatology</i> , 0, , .	1.9	0
570	A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0